Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442194 · ClinicalTrials.gov registry record
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 3,076
- Enrollment target
NCT01442194: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01442194 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,076 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01442194 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 3,076 participants
- Enrollment target
Study Summary
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.
Primary Outcome
Incidence of AEs for bradyarrhythmias, liver toxicity, macular edema, infections
Interventions
- DRUG Fingolimod
- DRUG other disease-modifying therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,076 participants |
| Start Date | 2011-08-01 |
| Est. Completion | 2020-07-10 |
What the finished NCT01442194 record still lists
NCT01442194 is an observational study that tracks outcomes without assigning an intervention. Its 3,076 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Fingolimod is the first listed.
NCT01442194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01442194 about?
NCT01442194 is a clinical study titled "Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies". The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall sa...
What is the current status of trial NCT01442194?
This trial is currently completed. The enrollment target is 3,076 participants. The study started on 2011-08-01. Estimated completion is 2020-07-10.
What interventions are being tested in trial NCT01442194?
The interventions under investigation include: Fingolimod (DRUG), other disease-modifying therapy (DRUG).
Who is sponsoring clinical trial NCT01442194?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI